A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...

An expert discusses how third line (3L) systemic therapy for metastatic renal cell carcinoma (mRCC) is guided by prior treatments, patient comorbidities, and drug-specific profiles. Options include ...

An expert discusses how medical professionals counsel patients on adverse event (AE) risks with tyrosine kinase inhibitors ...

Combination treatment with cadonilimab and lenvatinib can produce responses in patients with advanced endometrial cancer.